Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Preventing progression and disability in MS—when to treat?

Nature Reviews Neurology volume 9, pages 129–130 (2013)Cite this article

Subjects

In relapsing–remitting multiple sclerosis, conversion to the progressive stage is thought to be influenced by early relapses. Despite a new study suggesting that relapses do not drive long-term disability and proposing the latency period as an ideal target for therapeutic intervention, the relapsing phase remains a relevant treatment window.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tremlett, H. et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 9, 309–317 (2009).

    Google Scholar 

  2. Scalfari, A. et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133, 1914–1929 (2010).

    Article  Google Scholar 

  3. Scalfari, A. et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. Arch. Neurol. http://dx.doi.org/10.1001/jamaneurol.2013.599.

  4. Confavreux, C. & Vukusic, S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin. Neurol. Neurosurg. 108, 327–332 (2006).

    Article  Google Scholar 

  5. Confavreux, C. et al. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343, 1430–1438 (2000).

    Article  CAS  Google Scholar 

  6. Lublin, F. D., Baier, M. & Cutter, G. R. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61, 1528–1532 (2003).

    Article  Google Scholar 

  7. Lassmann, H., Brück, W. & Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7, 115–121 (2001).

    Article  CAS  Google Scholar 

  8. Wilkins, A. & Scolding, N. Protecting axons in multiple sclerosis. Mult. Scler. 14, 1013–1025 (2008).

    Article  CAS  Google Scholar 

  9. Renoux, C. Natural history of multiple sclerosis: long-term prognostic factors. Neurol. Clin. 29, 293–308 (2011).

    Article  Google Scholar 

  10. Pugliatti, M. et al. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. Acta Neurol. Scand. Suppl. 126, 24–30 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 10, 07100, Sassari, Italy

    Maura Pugliatti

Authors
  1. Maura Pugliatti
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pugliatti, M. Preventing progression and disability in MS—when to treat?. Nat Rev Neurol 9, 129–130 (2013). https://doi.org/10.1038/nrneurol.2013.28

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.28

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing